

# Partnered Discovery



Isogenica has a track record of delivering clinical assets through collaborative partnerships.

Isogenica partnered discovery projects are tailored to achieve developable therapeutic candidate binders identified from our hugely diverse proprietary LlamdA™ VHH heavy chain, single domain antibody library. This de-risked approach from project outset sets the framework for joint success. All partnered projects are managed through regular project meetings and are solution and outcome focused.

## STATE-OF-THE-ART TECHNOLOGY

The humanised synthetic library retains critical camelid hallmark residues to confer optimised solubility and stability of LlamdA® antibodies.

Purely *in vitro*, Isogenica's LlamdA® enables speed and efficiency unmatched by animal immunisation.

DIVERSE



AUTOMATED  
DISCOVERY



BINDING  
MODES




HITS IN DAYS





## STARTING A PARTNERSHIP WITH ISOGENICA

Starting from partner target nomination, we ensure to thoroughly understand the project concept. By doing this, our Discovery Alliances team develop and implement a project plan designed to mitigate risk early on. Employing high throughput screening strategies, candidate VHH binders are identified quickly. Characterisation and refined screening narrows the panel of hits to the most developable leads fitting partner target product profile (TPP), which can be further optimised and formatted to enable the desired therapeutic outcome.



Our expertise in phage and CIS display technologies coupled with our extensive automation capabilities, allows hits to be identified quickly. A wide spectrum of functional assays are used to refine hit panels to lead candidates. Isogenica has the in-house capability to efficiently undertake and manage all discovery and development activities from programme start to completion. We take our partnered projects from target to IND contribution.

Our characterisation assay capabilities include cell-killing, enzymatic activity assessment, formatting and primary cell work, alongside other specialist assays. From high throughput screening and hit characterisation, through to lead optimisation, safety and CMC, we focus on improving the confidence to achieve clinical development and success at each step.




CDRs are the binding region for target protein epitopes

The CDR3 loop of VHH is long and protruding and has a prolate shape, exposing a convex paratope

Due to their hydrophilic surfaces, VHH can be easily linked to create dimers or higher order multimers

Small stable molecules (15kDa)



Each program is tailored to the specific needs of the partner through a transparent and collaborative approach. Regular communication on progress ensures that projects track the changing priorities and business needs of the partner. In building these relationships, we bring our extensive expertise and technologies together to effectively develop novel approaches to disease treatment.

**READY TO START YOUR NEXT PROJECT?**

Get in touch with our business development team:

T +44 1799 533 680

E [bd@isogenica.com](mailto:bd@isogenica.com)